Based on the results of in vivo and in vitro study, we propose an algorithm for the study of tumor cells and CSCs and CD3+CD8+ T-lymphocytes in order to improve the diagnosis of SCLC and increase the efficiency of chemotherapy assessment and its enhancement using reprogrammed T-lymphocytes (Figure 19). This evidence concerns the gene CD8A and neoplasm.